NEW YORK — Biora Therapeutics said on Tuesday that it has licensed its Preecludia rule-out test for preeclampsia to Avero Diagnostics for commercial development.
Under the terms of the deal, Avero — a former affiliate of Biora — will acquire the assets and intellectual property related to the protein biomarker assay in exchange for commercial milestone payments and low double-digit royalties on net sales to Biora.
Additional terms were not disclosed.
San Diego-based Biora previously operated as a women's health diagnostic company called Progenity, but in mid-2021 shifted its focus to drug delivery and therapeutics. As part of that change, it stopped sales of its Preparent Carrier Test, Innatal Prenatal Screen, Riscover Hereditary Cancer Test, and Resura Prenatal Test. It also sold Avero to Northwest Pathology for $10.9 million.
Earlier this year, Biora sold its patents related to determining the origin of cell-free DNA to Roche Diagnostics.